Resources
7 Results (showing 1 - 7)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/26/2023 (updated 3/26/2024)
This session provided a summary of the FY 21 Psychostimulant support grant year one findings and tips for ROCRP PS data collection. It provided insights into stigma associated with people who use stimulants and are impacted by stimulants as well as ways to address reducing stigma.
Posted 9/28/2023 (updated 3/27/2024)
The University of Vermont Center on Rural Addiction (UVM CORA), the University of Rochester, and the Fletcher Group have conducted an online survey assessing SUD stigma (including stigmatizing language), treatment needs and barriers, and concerns through the perspectives of rural, RCORP-affiliated practitioners. The data report explores the findings of the survey, including practitioner recommendations on improving access to OUD treatment.
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.
Posted 8/4/2021 (updated 4/2/2024)
This session provided an opportunity to learn how to encourage faith leaders how to engage in harm reduction activities.
Posted 11/17/2021 (updated 4/3/2024)
The National Academies of Science, Engineering, and Medicine defines stigma as a range of negative attitudes, beliefs and behaviors that are associated with certain conditions such as addiction. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), has been a leading voice in talking about the “chilling effect” stigma has on our ability to address substance use and addiction in our country. In an April 2020 perspective piece published in the New England Journal of Medicine and in her NIDA blog piece, Dr. Volkow explains how stigma can prevent people from seeking care and can even contribute to their continuing addiction. We encourage our visitors to read Dr. Volkow’s writings as well as to familiarize themselves with the efforts to reduce stigma led by the National Institutes of Health (NIH) including the NIH HEAL InitiativeSM, which has made addressing stigma a key element in their efforts to address opioid addiction.
Posted 4/28/2021 (updated 4/10/2024)
Many people use opioids and are at risk of overdose. Naloxone is an opioid antagonist used to counter the effects of opioid overdose. There is an increased availability of naloxone in New York City; however, many who use opioids decline no-cost naloxone even when offered. Others may have the medication but opt not to carry it and report that they would be reluctant to administer it if they were to witness an overdose.
Posted 5/12/2021 (updated 4/10/2024)
Drug overdose is a continuing epidemic that claimed the lives of over 67,000 Americans in 2018. Opioids, either alone or in combination with other substances, were responsible for approximately 70% of these deaths. Many of these lost lives and other opioid-related harms are preventable through the timely administration of the opioid reversal drug naloxone and, where appropriate, other follow-up care.